

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



Yestar Healthcare Holdings Company Limited

巨星醫療控股有限公司

(Incorporated in the Cayman Islands with limited liability)

(Stock Code: 2393)

**INSIDE INFORMATION
POSITIVE PROFIT ALERT**

This announcement is made by the Company pursuant to Rule 13.09 of the Listing Rules and the Inside Information Provisions (as defined under the Listing Rules) under Part XIVA of the Securities and Futures Ordinance (Chapter 571 of the Laws of Hong Kong).

The Board wishes to inform the Shareholders and the potential investors that, based on the preliminary review and assessment of the unaudited consolidated management accounts of the Group for the year ended 31 December 2017, the Group is expected to record an increase of not less than 25% in its consolidated net profit of the Group for the year ended 31 December 2017 as compared with that of the year ended 31 December 2016.

The Group is still in the process of finalizing its audited consolidated financial results for the year ended 31 December 2017. As such, this positive profit alert announcement is made solely on the basis of assessment by Board with reference to its unaudited consolidated management accounts for the year ended 31 December 2017 and the information currently available to the Board, which may be subject to further adjustments after further internal review by the Board and review by the external auditors of the Company.

Shareholders and potential investors are advised to exercise caution when dealing in the shares of the Company.

This announcement is made by Yestar Healthcare Holdings Company Limited (the “Company”, together with its subsidiaries, the “Group”) pursuant to Rule 13.09 of the Rules Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited (the “Listing Rules”) and the Inside Information Provisions (as defined under the Listing Rules) under Part XIVA of the Securities and Futures Ordinance (Chapter 571 of the Laws of Hong Kong).

The board of directors of the Company (the “Board”) wishes to inform the shareholders of the Company (the “Shareholders”) and the potential investors that, based on the preliminary review and assessment of the unaudited consolidated management accounts of the Group for the year ended 31 December 2017, the Group is expected to record an increase of not less than 25% in its consolidated net profit of the Group for the year ended 31 December 2017 as compared with that of the year ended 31 December 2016 (audited consolidated net profit of the Group for the year ended 31 December 2016 amounted to approximately RMB269,928,000). The substantial increase is mainly attributable to (1) the outstanding performance of our In Vitro Diagnostic business and (2) the consolidation of financial information of all non-wholly-owned subsidiaries of the Company upon completion of these acquisitions.

The Group is still in the process of finalizing its audited consolidated financial results for the year ended 31 December 2017. As such, this positive profit alert announcement is made solely on the basis of assessment by Board with reference to its unaudited consolidated management accounts for the year ended 31 December 2017 and the information currently available to the Board, which may be subject to further adjustments after further internal review by the Board and review by the external auditors of the Company. Details of the financial performance of the Group will be contained in the annual results announcement of the Group for the year ended 31 December 2017, which is expected to be published in March 2018.

Shareholders and potential investors are advised to exercise caution when dealing in the shares of the Company.

By Order of the Board
Yestar Healthcare Holdings Company Limited
Hartono James
Chairman, CEO and Executive Director

Hong Kong, 28 February 2018

As at the date of this announcement, the executive Directors are Mr. Hartono James, Ms. Wang Ying, Mr. Chan To Keung, Ms. Wang Hong and Mr. Chan Chung Man; the independent non-executive Directors are Dr. Hu Yiming, Mr. Karsono Tirtamarta (Kwee Yoe Chiang) and Mr. Sutikno Liky.